Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker

Dermatology. 2011;222(4):304-10. doi: 10.1159/000329428. Epub 2011 Jul 15.

Abstract

Amicrobial pustulosis of the folds (APF) is a recently described entity characterized by relapsing pustular lesions predominantly involving the cutaneous flexures and scalp. This disease typically occurs in association with systemic lupus erythematosus and a variety of other autoimmune diseases. We here describe an APF-like pustular eruption predominantly affecting the scalp, face and trunk, occurring during long-term infliximab treatment for Crohn's disease. Immunohistochemical staining of skin biopsy specimens for myxovirus resistance protein A, a marker for type 1 interferon-inducible proteins, showed increased staining in the epidermis and dermal mononuclear inflammatory infiltrate. Our observation further extends the spectrum of cutaneous adverse reactions potentially related to anti-tumor necrosis factor-α, the clinical context in which APF can occur as well as its clinical presentations.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Acute Generalized Exanthematous Pustulosis / chemically induced*
  • Acute Generalized Exanthematous Pustulosis / drug therapy
  • Acute Generalized Exanthematous Pustulosis / pathology
  • Amoxicillin-Potassium Clavulanate Combination / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Crohn Disease / drug therapy*
  • Dermatologic Agents / therapeutic use
  • Female
  • GTP-Binding Proteins / metabolism
  • Gastrointestinal Agents / adverse effects*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infliximab
  • Myxovirus Resistance Proteins
  • Neutrophils / pathology
  • Prednisolone / therapeutic use
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Gastrointestinal Agents
  • Myxovirus Resistance Proteins
  • Tumor Necrosis Factor-alpha
  • Amoxicillin-Potassium Clavulanate Combination
  • Prednisolone
  • Infliximab
  • GTP-Binding Proteins